FFFrancesca Franco

Francesca Franco

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesca Franco has a total of 15 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Practical Guidance for the Use of Control‐ IQ Technology During Physical Activity and Exercise

    by Sergio Di Molfetta, Jonida Haxhi, Francesca Franco, Giuseppe Papa, Andrea Rigamonti, Michael C. Riddell, Dessi P. Zaharieva, Othmar Moser

    Introduction: Use of automated insulin delivery (AID) systems during physical activity and exercise (PA) is safe and associated with improved glucose outcomes when compared with insulin pump therapy in manual mode and insulin pen therapy, provided that appropriate adjustments to insulin doses and carbohydrate intake are ensured. Aim: This expert guidance aimed to support healthcare professionals in educating Control‐IQ (Tandem Diabetes Care) users on PA management. Methods: Based on international recommendations, including the recent EASD/ISPAD position statement on AID and exercise, as well as on the authors' clinical experience, we developed practical flowcharts and accompanying information that provide step‐by‐step guidance for PA management in children, adolescents and adults with type 1 diabetes using the Control‐IQ technology. Results: Operational instructions were outlined across four different scenarios, with additional advice on insulin pump suspension where required. In each of the scenarios, we highlighted the possibility of activating a Personal Profile with more or less insulin, a unique feature of the Control‐IQ algorithm that can be used simultaneously with the Exercise Activity feature. Conclusion: We believe that this expert guidance, with its practical flowcharts, can help simplify decision‐making for Control‐IQ users.

  • Open Access

    Non Typical Type 1 Diabetes Mellitus Onset in a Child With Salt-Wasting Congenital Adrenal Hyperplasia

    by Federica Rodofile, Francesca Franco, Nicoletta Buccino, Paola Cogo

    Type 1 diabetes mellitus (T1DM) and congenital adrenal hyperplasia (CAH) are 2 complex endocrine disorders with neighboring genetic loci. We present a case of T1DM onset in a 6-year-old child, already affected by 21-hydroxylase deficiency (salt-wasting CAH) diagnosed at 18 days of age, who was referred to our clinic because of typical symptoms of diabetes despite nondiagnostic fasting blood glucose values. Further analysis revealed elevated glycated hemoglobin (HbA1c), low C-peptide, and specific autoantibodies suggesting the diagnosis of T1DM. Although he only started with rapid-acting insulin analogue before meals, he presented spontaneous episodes of hypoglycemia just before the morning hydrocortisone dose, due to an underdosed glucocorticoid intake. Based on continuous glycemic monitoring (CGM), his morning dose was increased and given earlier; then we decided to apply an advanced hybrid closed-loop insulin pump to maintain glycemic time in range above 70%. Fasting glucose in CAH patients can be lower due to underdosed glucocorticoid replacement therapy. HbA1c and CGM can help recognize T1DM onset and evaluate the correct dosage of corticosteroid therapy in CAH patients. New studies are needed to understand the therapeutic approach for a more specific treatment in case of coexistence of these diseases.


  • Sex differences in growth hormone response to growth hormone-releasing hormone

    by P. Benito López, L. Avila, M. S. Corpas, J. A. Jiménez, L. Cacicedo, F. Sánchez Franco

    The aim of the present study was to ascertain whether sex differences exist in GH response to GHRH, and the influence that menstrual cycle have on this response. A GHRH test was performed on nine healthy men and ten women on days one and twelve of the menstrual cycle. Basal GH levels, (mean ± SE) (7.98 ± 3.09 ng/ml in women and 0.13 ± 0.07 ng/ml in men, p < 0.05) as well as maximal GH response (40.17 ± 11.96 ng/ml in women and 9.63 ± 2.32 ng/ml in males, p < 0.01) were significantly higher in women than in men. In spite of a significant increase in estradiol levels during the menstrual cycle (75.88 ± 2.48 pg/ml on day one and 198.40 ± 28.65 pg/ml on day twelve, p < 0.01) neither basal plasma GH levels, nor GH response to GHRH were significantly different. In conclusion, these results confirm that GH response to GHRH is higher in women than in men, and that this difference is not modified during the first phase of the menstrual cycle.